Flashcards · Module 4
🧠 Dementias & Movement Disorders
4 of 4 cards published · read by the site’s author on 14 November 2026
How do you tell the 4 major dementias apart?
Needs clinical review
The Quick Comparison Table:
| Feature | Alzheimer (AD) | Lewy Body (DLB) | Vascular (VCI) | Frontotemporal (FTD) |
|---|---|---|---|---|
| Frequency | 60–70% | 10–15% | 15–20% | ~5–10% |
| Onset | Slow, sneaky | Fluctuating | Stepwise or sudden | Behavioral changes |
| First symptom | Forgetting recent events | Visual hallucinations | Slow thinking, poor planning | Personality change, rudeness |
| Memory | Lost early | Less affected early | Relatively preserved early | Preserved early |
| Movement | Normal early | Parkinsonism | Focal neuro signs | Usually normal early (MND or parkinsonian features can develop) |
| Special feature | — | REM sleep disorder + extreme drug sensitivity | White matter lesions on MRI | Compulsive behaviors, sweet cravings |
The Reality After Age 85:
MIXED pathology is common (AD + vascular + Lewy bodies). Pure single-cause dementia is the exception, not the rule.
Sources checked (14) · 14 November 2026
- Multimodal neuroimaging in Alzheimer's disease: A practical, case-illustrated review of quantitative MRI and molecular PET (2026)
- Dementia with Lewy bodies - from scientific knowledge to clinical insights (2019)
- From empirical efficacy to neurovascular and cerebrovascular systems perspective: a bibliometric and visualized analysis of traditional Chinese medicine for vascular dementia (2026)
- Clinical Subtypes of Frontotemporal Dementia (2013)
- Epidemiologic and clinical features of Alzheimer's disease: a hospital study based on the memory clinic in Abidjan, Côte D'ivoire, Sub-Saharan Africa (2026)
- Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium (2017)
- The Utility of Addenbrooke's Cognitive Examination III (ACE-III) in Differentiating Neurodegenerative Disorders with Psychotic Symptoms: A Narrative Review (2026)
- Back to Basics: A Clinical Diagnosis of Behavioural Variant Frontotemporal Dementia (bvFTD) (2026)
- Clinical Trajectories of Neurodegenerative Diseases in Older Adults: A Three-Sphere Framework for Precision Geriatric Neurology (2026)
- Vascular dementia: emerging trends (2007)
- Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011)
- Vascular Dementia: From Pathophysiology to Therapeutic Frontiers (2025)
- Clinical and imaging correlates of hyperorality in syndromes associated with frontotemporal lobar degeneration (2024)
- Dementia in the oldest old: a multi-factorial and growing public health issue (2013)
Why can Haloperidol KILL a patient with Lewy Body Dementia?
Needs clinical review
The Danger:
Up to 50% of DLB patients have severe neuroleptic sensitivity. Giving a D2 blocker like Haloperidol can cause:
⚡ Catastrophic rigidity (can't move at all)
⚡ Extreme sedation
⚡ Autonomic collapse (blood pressure crashes)
⚡ Neuroleptic Malignant Syndrome-like picture
⚡ Sudden death
If You MUST Treat Hallucinations in DLB:
First choice: Optimize Cholinesterase Inhibitors (Rivastigmine, Donepezil) — they reduce hallucinations by boosting acetylcholine
If desperate: Very low-dose Quetiapine (12.5–25 mg) — low D2 receptor affinity
Newest option: Pimavanserin — a 5-HT2A inverse agonist with zero D2 blocking
Sources checked (7) · 14 November 2026
- Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium (2005)
- Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium (2017)
- A Review of Dementia with Lewy Bodies' Impact, Diagnostic Criteria and Treatment (2018)
- Lewy Body Dementia (2024)
- Neuroleptic sensitivity in patients with senile dementia of Lewy body type (1992)
- Advances in the Diagnosis and Management of Psychotic Symptoms in Neurodegenerative Diseases: A Narrative Review (2023)
- Management of Parkinson's disease psychosis-a European perspective (2026)
Note: Pimavanserin is approved by the US Food and Drug Administration for treating hallucinations and delusions in Parkinson's disease psychosis. (Impact of Early Treatment with Pimavanserin on Healthcare Resource Utilization Among Newly Diagnosed Patients with Parkinson's Disease Psychosis: A Pre-Post Medicare Claims Database Analysis (2026))
Alzheimer's Disease: The Amyloid Cascade in Simple Terms
Needs clinical review
Step-by-Step Pathology:
1. A normal protein (APP) sits in the neuron membrane
↓
2. Two enzymes (β-secretase + γ-secretase) cut APP into small pieces
↓
3. One piece = Aβ42 — sticky, toxic, clumps together
↓
4. Aβ42 clumps form AMYLOID PLAQUES outside neurons
↓
5. Inside neurons, TAU protein detaches from microtubules
↓
6. Tau forms NEUROFIBRILLARY TANGLES (NFTs)
↓
7. Synapses die → Neurons die → Brain shrinksThe Biomarker Signature:
| Test | Finding in AD |
|---|---|
| CSF Aβ42 | LOW (it's stuck in brain plaques, not flowing in CSF) |
| CSF Total Tau | HIGH (neurons are dying and releasing tau) |
| CSF p-Tau (181/217) | HIGH (tangles are forming) |
| Amyloid PET scan | Positive (lights up) |
| Tau PET scan | Follows Braak staging pattern |
Key Concept — Braak Staging:
Tau tangles spread in a predictable path:
Entorhinal cortex → Hippocampus → Diffuse neocortex
(This is why memory goes first, then language, then everything else)
Sources checked (6) · 14 November 2026
- A synapse perspective on the function of the amyloid precursor protein (2025)
- Beyond Amyloid and Tau: The Critical Role of Microglia in Alzheimer's Disease Therapeutics (2025)
- Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease (2017)
- Alzheimer disease (2017)
- CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease (2023)
- (18)F-FDG-PET and Multimodal Biomarker Integration: A Powerful Tool for Alzheimer's Disease Diagnosis (2025)
How do you tell Parkinson's Disease from the "look-alikes"?
Needs clinical review
The Real Deal — Parkinson's Disease (PD):
Asymmetric onset (one side worse)
Resting tremor (4–6 Hz "pill-rolling")
Rigidity + Bradykinesia
Excellent response to Levodopa
Falls happen late (recurrent falls within 3 years are a red flag)
The Red Flag Look-Alikes:
| Diagnosis | Key Red Flag That Rules Out PD |
|---|---|
| PSP (Progressive Supranuclear Palsy) | Can't look DOWN (vertical gaze palsy) + early backward falls + symmetric axial rigidity |
| MSA (Multiple System Atrophy) | Severe early autonomic failure (fainting, incontinence) + poor levodopa response |
| DLB (Lewy Body Dementia) | Dementia comes FIRST (within 1 year of motor symptoms) |
| Drug-Induced Parkinsonism | Symmetric, often without rest tremor, history of antipsychotic/metoclopramide use |
The "1-Year Rule" for DLB vs. PD Dementia:
Dementia before or within 1 year of parkinsonism = DLB
Dementia >1 year after established parkinsonism = PD Dementia (PDD)
Sources checked (6) · 14 November 2026
- Defining Parkinson's Disease: Past and Future (2024)
- Tremor Syndromes: An Updated Review (2021)
- Assessment of Mitochondrial DNA Copy Number in Progressive Supranuclear Palsy Patients: Evidence From a Pilot Study (2026)
- The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (2022)
- Drug-induced parkinsonism: a review (1994)
- Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium (2017)